These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37875567)

  • 1. Effects of the novel selective κ-opioid receptor agonist NP-5497-KA on morphine-induced reward-related behaviors.
    Ide S; Hirai T; Muto T; Yamakawa T; Ikeda K
    Sci Rep; 2023 Oct; 13(1):18164. PubMed ID: 37875567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference.
    Ide S; Iwase N; Arai K; Kojima M; Ushiyama S; Taniko K; Ikeda K
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.
    Taylor AM; Roberts KW; Pradhan AA; Akbari HA; Walwyn W; Lutfy K; Carroll FI; Cahill CM; Evans CJ
    Br J Pharmacol; 2015 Jan; 172(2):691-703. PubMed ID: 24923251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
    Zhou Y; Kreek MJ
    Alcohol Clin Exp Res; 2019 Jun; 43(6):1077-1090. PubMed ID: 30908671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
    Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
    J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
    Zhou Y; Kreek MJ
    Brain Res; 2019 Dec; 1724():146410. PubMed ID: 31469985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
    Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
    Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
    Dunn A; Windisch K; Ben-Ezra A; Pikus P; Morochnik M; Erazo J; Reed B; Kreek MJ
    Psychopharmacology (Berl); 2020 Aug; 237(8):2405-2418. PubMed ID: 32435819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.
    Atigari DV; Paton KF; Uprety R; Váradi A; Alder AF; Scouller B; Miller JH; Majumdar S; Kivell BM
    Neuropharmacology; 2021 Mar; 185():108445. PubMed ID: 33383089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
    Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
    Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats.
    Zamarripa CA; Patel TR; Williams BC; Pareek T; Schrock HM; Prisinzano TE; Freeman KB
    Behav Pharmacol; 2020 Dec; 31(8):792-797. PubMed ID: 32804774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
    Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
    Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
    Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
    J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5.
    Glück L; Loktev A; Moulédous L; Mollereau C; Law PY; Schulz S
    Biol Psychiatry; 2014 Nov; 76(10):767-74. PubMed ID: 24629717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
    Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
    Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour.
    Brice-Tutt AC; Wilson LL; Eans SO; Stacy HM; Simons CA; Simpson GG; Coleman JS; Ferracane MJ; Aldrich JV; McLaughlin JP
    Br J Pharmacol; 2020 Sep; 177(18):4209-4222. PubMed ID: 32562259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.